Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials

This publication has 37 references indexed in Scilit:

• Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
  New England Journal of Medicine, 2019
• One-stage dose–response meta-analysis for aggregated data
  Statistical Methods in Medical Research, 2018
• Targeting GLP-1 receptor trafficking to improve agonist efficacy
  Nature Communications, 2018
• Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
  The Lancet Diabetes & Endocrinology, 2018
• Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
  Diabetes, Metabolic Syndrome and Obesity, 2017
• Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): D ata from randomized controlled trials
  Diabetes, Obesity and Metabolism, 2017
• A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
  New England Journal of Medicine, 2015
• Deploying an interactive machine learning system in an evidence-based practice center
  2012
• Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization
  Current Medical Research and Opinion, 2009
• G Protein–Coupled Receptor Sorting to Endosomes and Lysosomes
  Annual Review of Pharmacology and Toxicology, 2008